FDA Review Timelines by Pathway and Product Type
Accurate timeline expectations are foundational to development planning, investor communications, and submission strategy. Underestimating or overestimating FDA review duration can misalign clinical hold periods, commercial launch readiness, and resource allocation across regulatory and manufacturing teams.
This analysis draws on FDA submission records, approval letters, and decision documents to characterize actual calendar time from submission receipt to agency decision across the major marketing pathways—510(k), De Novo, PMA, NDA, and BLA—broken down by review track and product type.
Want to ask Rhizome your own regulatory questions? Try it for free.
How long FDA review actually takes, by pathway and product type
Review time is not one number. It depends heavily on the marketing pathway and, within each pathway, on the product's complexity and review track. Measured from the date FDA received the submission to the date of the agency's decision, the median clearance or approval ranges from roughly four months for a 510(k) device to more than a year for a standard-review biologic. The figures below are computed directly from the receipt and decision dates in FDA's own submission records (device clearances and De Novo grants) and from the "dated and received" language in approval letters and PMA decision documents (drugs, biologics, and Class III devices).
At a glance, the median calendar time from submission to decision falls into three bands:
| Pathway / product type | Median | Typical middle 50% (p25–p75) | What it covers |
|---|---|---|---|
| 510(k) (all clearances) | ~128 days (4.2 mo) | 70–228 days | Moderate-risk devices cleared by substantial equivalence 12 |
| NDA, priority review | ~240 days (7.9 mo) | 231–245 days | New drugs on the 6-month priority track 2679026776 |
| BLA, priority review | ~243 days (8.0 mo) | 238–275 days | Biologics on the priority track 2729527310 |
| PMA original (Class III) | ~252 days (8.3 mo) | 180–520 days | Highest-risk devices, filing to approval 2281122801 |
| De Novo | ~299 days (9.8 mo) | 170–423 days | Novel low-to-moderate-risk devices with no predicate 30413042 |
| NDA, standard review | ~347 days (11.4 mo) | 303–449 days | New drugs on the 10-month standard track 2686226756 |
| BLA, standard review | ~408 days (13.4 mo) | 365–595 days | Biologics on the standard track 2729427299 |
Devices: the 510(k) is the fast lane, PMA and De Novo are not
The 510(k) is by far the highest-volume and quickest pathway. Across roughly 3,000 clearances per year, the median time from receipt to a substantial-equivalence decision sits around four months, but the spread is wide: a quarter of clearances land inside about 70 days while the slowest quarter run past 228 days, and the 90th percentile reaches roughly 270 to 395 days depending on the year 12. That spread is the "product type" story inside the pathway. Simpler, well-characterized device types with mature predicates clear fastest, while device types that routinely need additional information, clinical data, or novel testing sit at the long end. Among the highest-volume product codes over 2019 to 2025, median review times ranged from roughly 65 to 90 days for the quickest categories to more than 200 days for the slowest, a threefold difference driven almost entirely by device complexity and review-question depth 1.
The 510(k) clock has also drifted over time. Median review time rose from about 118 days in 2019 to a peak of 144 days in 2022, coinciding with the pandemic-era submission surge and EUA workload, then eased back to about 126 days by 2025 12.
De Novo classification, used for novel devices that have no legal predicate, takes far longer: a median of about 299 days, with the middle half of grants running from roughly 170 to 423 days 30413042. Because each De Novo requires FDA to write special controls and establish a new device classification, review runs closer to a year than to a quarter, and year-by-year medians have held in the 296 to 331 day range since 2019 3041.
Original PMAs, the pathway for the highest-risk Class III devices, show a median filing-to-approval time of about 252 days (8.3 months) in the sampled cohort, but the distribution is heavily right-skewed. The middle half spans roughly 180 to 520 days, and the slowest tail extends well past three years for devices that go through advisory-panel review, major deficiency cycles, or manufacturing follow-up 2281123092. Straightforward PMAs, including several recent cardiovascular and electrophysiology devices, cleared filing to approval in about 6 months 2280122836, while more complex or panel-track submissions such as certain carotid-stent and combination systems ran 3 years or longer 23092. Two cautions apply to the PMA figure: it is measured from the FDA "filing" milestone (after the acceptance and filing review), which understates total submission-to-decision time, and the filing date is documented in only a minority of PMA decision records, so the sample is smaller and less complete than the device-clearance and drug figures.
Drugs and biologics: the review track matters more than the molecule
For new drugs (NDAs) and biologics (BLAs), the single biggest determinant of review time is whether FDA granted priority review. The pattern in the approval-letter data is striking in its consistency.
Priority-review NDAs cluster tightly around a median of about 240 days from receipt to action, with the interquartile range spanning just 231 to 245 days 2679026776. Priority BLAs behave almost identically, at a median near 243 days 2729527310. That tight clustering, roughly eight months from submission, reflects the priority-review construct working as designed: a six-month goal measured from the 60-day filing date, which lands most first-cycle priority approvals right around the eight-month calendar mark.
Standard-review products take substantially longer. Standard NDAs run a median of about 347 days (11.4 months) 2686226756, and standard BLAs a median of about 408 days (13.4 months) 2729427299. Biologics on the standard track are the slowest of the major pathways studied, consistent with the added chemistry, manufacturing, and controls and facility-inspection burden that accompanies a biologic license.
The other defining feature of the drug and biologic data is a long right tail that pulls the mean well above the median. For priority NDAs, the median is about 240 days but the mean is roughly 310 days; for standard BLAs, the median is about 408 days but the mean exceeds 520 2679027299. That gap is the fingerprint of the complete response letter (CRL) and resubmission cycle. Applications that receive a CRL and are later approved carry a submission-to-approval span measured from the original receipt date, so a second review cycle can push total elapsed time past two or three years even on a nominally priority molecule. Several products in the priority cohort recorded submission-to-approval spans of 1,000 days or more for exactly this reason 26790. In other words, most drugs approved on the first cycle track their PDUFA goal closely, but a meaningful minority take dramatically longer, and that minority is invisible if you look only at the median.
What this means for planning
Three practical takeaways follow from the data. First, pathway choice dominates the timeline: a 510(k) is a roughly four-month proposition while a standard BLA is closer to thirteen months, and no amount of submission quality closes that structural gap. Second, within the drug and biologic pathways, securing priority review is worth roughly three to five months of calendar time, and the benefit is remarkably reproducible across products 2679027295. Third, the median understates risk: for PMAs and for any drug or biologic exposed to a possible CRL, the planning-relevant number is not the median but the tail, where second review cycles and panel processes add one to three years 2309227299.
A few measurement caveats are worth keeping in view. The device figures are true calendar time from FDA receipt to decision, drawn from the full population of clearances and De Novo grants, so they are the most complete. The drug and biologic figures come from a verified sample of recent original approvals (2022 to 2025) in which the extracted approval date was cross-checked against the metadata decision date to confirm the correct letter, which makes each data point reliable but the medians representative of a sample rather than the entire cohort. The PMA figure is the least complete, for the reasons noted above. For a specific program, the most defensible estimate combines the pathway median here with the product-type detail and the tail risk relevant to that submission.